Announced details
Chronic motor paralysis associated with traumatic brain injury
Second post-marketing administration. The first post-marketing administration was carried out at Hokkaido University Hospital on 2 October 2026, and the second at Okayama University Hospital on 27 October 2026.
Okayama University Hospital is the medical institution and administration site where SanBio’s regenerative medicine product was administered. Capital and personnel relationships are not disclosed.
The location, representative, capital, year of establishment and other details are not disclosed. It is stated to be a university hospital.
Product covered by the Sakigake Designation System, RMAT designation, and Advanced Therapy Medicinal Product (ATMP) designation
Ministry of Health, Labour and Welfare; U.S. Food and Drug Administration (FDA); European Medicines Agency (EMA)
Conditional and time-limited marketing approval was obtained on 31 July 2024. The approval number and expiry date are not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
James SL et al., Global Burden of Disease Study 2016(Lancet Neurol 2019);Selassie AW et al.(J Head Trauma Rehabil 2008);Zaloshnja E et al.(J Head Trauma Rehabil 2008)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Akugo® Intracerebral Implant Injection (generic name: vandefitemcel) |
| Counterparty | Okayama University Hospital |
| Counterparty overview | The location, representative, capital, year of establishment and other details are not disclosed. It is stated to be a university hospital. |
| Relationship with the Company | Okayama University Hospital is the medical institution and administration site where SanBio’s regenerative medicine product was administered. Capital and personnel relationships are not disclosed. |
| Launch date | 27 October 2026 (actual: administered at Okayama University Hospital) |
| Applicable area | Chronic motor paralysis associated with traumatic brain injury |
| Award/certification name | Product covered by the Sakigake Designation System, RMAT designation, and Advanced Therapy Medicinal Product (ATMP) designation |
| Awarding / certifying body | Ministry of Health, Labour and Welfare; U.S. Food and Drug Administration (FDA); European Medicines Agency (EMA) |
| Registration number and expiry date | Conditional and time-limited marketing approval was obtained on 31 July 2024. The approval number and expiry date are not disclosed. |
| Usage history | Second post-marketing administration. The first post-marketing administration was carried out at Hokkaido University Hospital on 2 October 2026, and the second at Okayama University Hospital on 27 October 2026. |
| Source | James SL et al., Global Burden of Disease Study 2016(Lancet Neurol 2019);Selassie AW et al.(J Head Trauma Rehabil 2008);Zaloshnja E et al.(J Head Trauma Rehabil 2008) |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The administration was carried out after the prescribed procedures had been completed. The company explained that the patient’s postoperative course would continue to be monitored carefully at Okayama University Hospital.